Comparing IntelliPharmaCeutics Intl (IPCI) and Concordia International (CXRX)
IntelliPharmaCeutics Intl (NASDAQ: IPCI) and Concordia International (NASDAQ:CXRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.
Insider and Institutional Ownership
3.4% of IntelliPharmaCeutics Intl shares are held by institutional investors. Comparatively, 8.8% of Concordia International shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares IntelliPharmaCeutics Intl and Concordia International’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|IntelliPharmaCeutics Intl||$2.25 million||12.96||-$10.14 million||($0.35)||-2.40|
|Concordia International||$816.16 million||0.03||-$1.32 billion||($35.54)||-0.01|
IntelliPharmaCeutics Intl has higher earnings, but lower revenue than Concordia International. IntelliPharmaCeutics Intl is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
IntelliPharmaCeutics Intl has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Concordia International has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.
This table compares IntelliPharmaCeutics Intl and Concordia International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and recommmendations for IntelliPharmaCeutics Intl and Concordia International, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
IntelliPharmaCeutics Intl currently has a consensus price target of $2.37, suggesting a potential upside of 181.75%. Concordia International has a consensus price target of $0.50, suggesting a potential downside of 3.85%. Given IntelliPharmaCeutics Intl’s stronger consensus rating and higher probable upside, equities research analysts plainly believe IntelliPharmaCeutics Intl is more favorable than Concordia International.
IntelliPharmaCeutics Intl beats Concordia International on 8 of the 12 factors compared between the two stocks.
IntelliPharmaCeutics Intl Company Profile
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.
Concordia International Company Profile
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
Receive News & Ratings for IntelliPharmaCeutics Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.